Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
Status:
Recruiting
Trial end date:
2025-09-26
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the efficacy and safety of darolutamide in combination
with standard androgen deprivation therapy (ADT) in patients with metastatic hormone
sensitive prostate cancer.